Therapeutic efficacy of lanoconazole, a new imidazole antimycotic agent, for experimental cutaneous candidiasis in guinea pigs.
The therapeutic efficacy of 1% cream and 1% solution of lanoconazole, a new imidazole antimycotic agent, in the model of cutaneous candidiasis in prednisolone-treated guinea pigs was evaluated in comparison with that of comparable formulations of bifonazole. Each preparation was topically applied once a day for 3 consecutive days, starting on the fifth day postinfection, and quantitative culture study wsa conducted on the ninth day postinfection. Both formulations of lanoconazole were much more highly effective in terms of eradication of fungi than the bifonazole formulations.
Niwano
Y
Y
Pharmaceutical Research Institute, Nihon Nohyaku Co., Ltd., Osaka, Japan.
Seo
A
A
Kanai
K
K
Hamaguchi
H
H
Uchida
K
K
Yamaguchi
H
H
D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects; D002179:Candidiasis, Cutaneous / Q000188:drug therapy*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D011239:Prednisolone / Q000494:pharmacology
D000935:Antifungal Agents; D006571:Heterocyclic Compounds; D007093:Imidazoles; C072774:latoconazole; D011239:Prednisolone; C036596:bifonazole